Why do new strains of HIV spread slowly?
Most HIV epidemics are still dominated by the first strain that entered a particular population. New research published in PLOS computational biology offers an explanation of why the global mixing of HIV variants is so slow.

Single strains of HIV entered distinct populations across the world to establish local epidemics. Once established, these epidemics are resilient to the introduction of new strains, thus conserving "founder effects."
Ferdinandy et al.
Researchers from Eötvös Loránd University; Bence Ferdinandy, Dr Viktor Müller, and colleagues, analyzed simulated epidemics to understand how distinct HIV virus strains spreading in the same population compete and interfere with each other.
The authors show that once a strain of HIV has established a stable epidemic, it can slow down the invasion of secondary strains into the population. The primary factor is because individuals infected with the first HIV strain survive for a relatively long time and are resilient to 'superinfection' from a second strain. The individuals effectively impose 'roadblocks' for the spread of invader strains in the network of sexual contacts.
The results imply that the HIV variants that dominate the global epidemic today may not be the most transmissible strains: they may simply have been the 'luckiest', picked up by chance to ride the first wave of expansion from the epicenter of the pandemic in Central Africa.
More transmissible strains are likely to exist or be created by mutation and recombination, and these strains may eventually outgrow the current variants, a warning that the pandemic is not 'static': it may grow further on a longer time scale. In contrast, eliminating the epidemic could increase the risk of emergent HIV lineages from novel cross-species transmissions.
Original publication
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Does obesity start in the brain? - Specialised nerve cells increase the appetite for high-fat foods
Detailed insight into stressed cells - Researchers develop new protoeomics procedure

LABOMATIC Instruments AG - Möhlin, Switzerland
SYGNIS plans to acquire profitable proteomics player - Combined 2016 pro-forma revenues to exceed EUR 5 million
The circular economy – resource-efficient and digital - Can the digital transformation pave the way for resource-efficient materials cycles?
Category:Chemopreventive_agents
Category:Oral_Surgery
Avesthagen
Category:Herbals
Dorsalis_pedis_artery
Genset_Corporation
